CA
LXEO icon

Clearstead Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Clearstead Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$40 – 2598
2025
Q4 		$40 Sell
4
-300
-99% -$2.74K ﹤0.01% 2634
2025
Q3 		$2.02K Buy
+304
New +$1.47K ﹤0.01% 2445

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clearstead Advisors's LXEO Position: Q1 2026 in Review

Clearstead Advisors sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 4 shares — an estimated $40 sold.

Clearstead Advisors first reported a position in LXEO in Q3 2025 and held it in 2 quarters. The position peaked at $2.02K in Q3 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Clearstead Advisors reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Clearstead Advisors sold 4 Lexeo Therapeutics shares in Q1 2026, an estimated $40.
  • Clearstead Advisors first reported a position in Lexeo Therapeutics in Q3 2025 and held it in 2 quarters.
  • Clearstead Advisors's Lexeo Therapeutics position peaked at $2.02K in Q3 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.